Securing-Iodine

The global growth of Computed Tomography (CT) procedures is leading to increased global demand for iodine contrast media (ICM). Based on this advancement, we estimate that volume demand for ICM will double in the next ten years¹.

In order to secure future supply, significant investment is needed which includes a 4-STEP PLAN: securing a long-term iodine supply, producing more Active Pharmaceutical Ingredient (API) for ICM in our primary manufacturing site, producing more doses in our secondary fill & finish manufacturing sites and maximising the use of iodine contrast media.

1. Securing Long-Term Agreements to Ensure Future Iodine Supply

GE Healthcare have established a long-term agreement enabling us to secure increasing supply of iodine, a key ingredient for contrast media products used in X-Ray and CT imaging procedures.

The agreement will see an increase supply of iodine raw material year-on-year and is part of GE Healthcare’s broader commitment and investment plan to enable the production of 30% more patient doses of ICM annually by 2025¹.

2. Producing More API For More Iodine Contrast Media

In our Lindesnes site, we are investing to expand our active pharmaceutical ingredient (API) capacity by ~30% by 2025¹ .

3. Producing More Doses in Our Secondary Manufacturing Fill and Finish Sites

We’re investing to expand capacity at our fill and finish facilities to produce ~30% more patient doses by 2025¹.

As part of this, GEHC are investing in production capacity to help meet this growing demand, including a new $30 million manufacturing line at its Cork, Ireland, contrast media production facility, which opened in 2022.

4. Maximized Usage of ICM by Enabling Personalized Dosing, Improved Workflow and return of ICM for re-use

To enable more patient throughput, personalized dosing, larger multidose package and iodine recycling we are:

New scanners with smart protocols, AI and other tools to help deliver the right dose
Manufacturing ICM in larger, multidose +PLUSPAK™ polymer packaging, reducing downtime from breakages and metal ring pull injuries²
Capturing iodine for re-use through our production processes, return of unsaleable product, customer return of unused contrast media (in some markets)

Costs are Increasing

Price of iodine has increased by 120% from 2019 to 2022 with rises set to continue³

Pricing will face further pressure with global inflation predicted to be 6%-10% this year⁴

Learn more about how we are securing our iodine supply

If you want to learn more about how we are securing our iodine supply, please complete the form below and we will provide you with all the information needed

First Name:

Last Name:

Hospital/Company Name:

Title:

Role:

Phone Number:

Work Email Address:

Postcode:

Country

Comments

By clicking here, you are agreeing to receive marketing emails, newsletters and other promotional communications from GE Healthcare from time to time.

utm_campaign:

utm_content:

utm_medium:

utm_source:

utm_term:

Product Information

Please see Omnipaque^TM product information here for:

Please see Visipaque^TM product information here for:

Reporting Adverse Events

GE Healthcare has a legal and ethical responsibility to protect the public health and therefore we ensure safety and efficiency for our products.

In order to do so, we collect reports about suspected adverse events that the patients experience during or after they are exposed to our products.

We also collect information about special situations (such as exposure during pregnancy, overdose, etc. ) as well as customer complaints and other views from customers about our products.

To report a suspected adverse event/special situation, customer complaint or just to share your views about our products, please contact:

For Sweden: [email protected] | Phone: 0200 895473
For Finland: [email protected] | Phone: 0800 919 427
For Denmark: [email protected] | Phone: 45 80 88 95 14 or 45 70 22 22 03
For Norway: [email protected] | Phone: 23 18 79 58
For Netherlands: [email protected] | Phone: 31 40 299 1111
For BELUX: [email protected] or [email protected] | Phone: France 32 80 04 96 18 | Netherlands 32 80 03 89 97

REFERENCES

Data on file. GE Healthcare Planned Investment; 2022
Marshall G. Radiography. 2008;14:128-134.
Merchant Research & Consulting Ltd. Iodine: 2022 World Market Review and Forecast to 2031. https://mcgroup.co.uk/researches/iodine. Accessed 31 July, 2022.
Upply. An increase in transportation prices, a factor for inflation in 2021? https://market-insights.upply.com/en/an-increase-in-transportation-prices-a-factor-for-inflation-in-2021.

GE Healthcare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe

GE Healthcare Limited, Pollards Wood, Nightingales Lane, Chalfont St Giles, Buckinghamshire, England HP8 4SP

© 2023 GE HealthCare
Omnipaque and Visipaque are trademarks of GE HealthCare.
GE is a trademark of General Electric Company used under trademark license.

JB00023NEU | January 2023

Welcome to GE Healthcare